Company
Sinopep (688076.SH) is a trusted CDMO specializing in end-to-end CMC development and cGMP manufacturing of peptide, oligonucleotide, and small molecule APIs. With nearly 15 years of experience, we support global pharmaceutical and biotech partners from early-phase development through commercialization. Our services include process and analytical method development, validation, stability studies, and regulatory support for global filings (IND/NDA). Since 2009, Sinopep has passed four U.S. FDA inspections and operates in strict compliance with FDA and ICH guidelines. We are also the world’s leading exporter by volume of Semaglutide, Tirzepatide, and Liraglutide APIs—trusted by top pharmaceutical companies for commercial supply.
With one of the world’s most flexible production capacities—ranging from milligram-scale discovery to 200+ kg commercial batches—we help accelerate drug development by prioritizing early-phase CMC readiness and delivering Phase 3–ready packages as early as Phase 2b, supporting fast-track and breakthrough therapy programs.